By Jennifer Chiou
New York, Oct. 3 - Tessera, Inc. announced the completion of $8.5 million in series B financing.
"We have one product in the marketplace now and have, through our relationships with Johns Hopkins University and the University of Pittsburgh, developed impressive data for highly specific and sensitive blood tests," chairman and chief executive officer Ray Cairncross said in a news release.
"We will now prepare this breakthrough technology for clinical trials and commercialization."
Based in Seattle, Tessera is a biomedical company focused on products for the early detection of prostate and colon cancer. It has ProstaMark EPCA, an analyte-specific reagent for use in pathology laboratories on tissue samples taken in prostate biopsies.
| Issuer: | Tessera, Inc.
|
| Issue: | Preferred stock
|
| Amount: | $8.5 million
|
| Round: | Series B
|
| Announcement date: | Oct. 3
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
